Karyopharm Presents Clinical Data for Selinexor (KPT-330) in Patients With Heavily Pretreated Gynecological Cancers and Asian Patients With Advanced Malignancies at 2015 ASCO Annual Meeting
NEWTON, Mass., May 30, 2015 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of positive clinical data for its lead product candidate, Selinexor (KPT-330), a first-in-class, oral Selective Inhibitor of Nuclear Export / SINE™ compound, at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. In an ongoing Phase 2 clinical trial evaluating the activity of single-agent selinexor in patients with heavily pre-treated, progressive gynecological cancers, oral selinexor showed promising anti-tumor activity or disease control across ovarian, endometrial and cervical cancers with disease control rates of up to 62% and several patients remaining on study for up to 12 months. In a Phase 1 clinical trial evaluating the activity of selinexor in Asian patients with advanced malignancies, single-agent selinexor demonstrated anti-tumor activity across a variety of malignancies in this patient population.
TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab)
WALTHAM, Mass. and KENILWORTH, N.J., May 30, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced a collaboration to evaluate the combination of TESARO's niraparib plus Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in a Phase 1/2 clinical trial.
Adaptimmune Announces Data From Clinical Studies of NY-ESO-1 Specific T-Cells in Multiple Cancers at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting
OXFORD, England and PHILADELPHIA, May 30, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers. Eighty-two (82) patients have been treated to date with NY-ESO-T; 44 under Adaptimmune's IND, and 38 under a National Cancer Institute IND (Robbins et al., CCR, 2014). The data from Adaptimmune's clinical studies in synovial sarcoma, multiple myeloma and ovarian cancer were presented at the 2015 Annual American Society of Clinical Oncology (ASCO) Meeting.
Interior Office Solutions
IOS Debuts New Downtown L.A. Office, First WELL Building Furniture Dealership Site in the World
LOS ANGELES, May 30, 2015 (GLOBE NEWSWIRE) -- Interior Office Solutions (IOS), a contract furniture firm with facilities in California and Oregon, is a Haworth Preferred & "Best in Class" Dealership. IOS is celebrating 15 years of service and hosted a grand opening party Thursday (May 28) in their WELL certified downtown showroom located in the Citicorp Tower (LEED Certified) at 444 S. Flower Street, Suite 200, Los Angeles. The WELL Building Standard is a performance-focused system for measuring, certifying, and monitoring features of the built environment that impact human health and wellbeing including air, water, nourishment, light, fitness, comfort, and mind.
MacroGenics Presents Updated Data from Phase 1 Study of Margetuximab at ASCO Annual Meeting 2015
ROCKVILLE, Md., May 30, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, announced that updated results of the Phase 1 study of margetuximab were reported during a poster session today at the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO). Howard A. Burris III, M.D., FACP, Chief Medical Officer of Sarah Cannon Research Institute, and first author presented "Updated findings of a first-in-human, phase 1 study of margetuximab, an Fc-optimized chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors," during the Breast Cancer HER2/ER poster session. The primary objective of the study was to evaluate safety of margetuximab using two dosing regimens. Margetuximab was found to be well-tolerated at all doses.